Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
Takashi KawaharaYasuhide MiyoshiSahoko NinomiyaMotoki SatoTeppei TakeshimaHisashi HasumiKazuhide MakiyamaHiroji UemuraPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Bone metastatic CRPC patients who received Ra-223 showed a significantly better prognosis than bone metastatic CPRC patients who did not receive Ra-223.
Keyphrases
- squamous cell carcinoma
- bone mineral density
- small cell lung cancer
- end stage renal disease
- rheumatoid arthritis
- soft tissue
- bone loss
- ejection fraction
- bone regeneration
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- postmenopausal women
- prognostic factors
- ankylosing spondylitis
- body composition
- systemic lupus erythematosus
- adverse drug
- patient reported